Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
J Am Acad Dermatol
; 58(1): 106-15, 2008 Jan.
Article
em En
| MEDLINE
| ID: mdl-17936411
ABSTRACT
BACKGROUND:
Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis.OBJECTIVE:
We sought to evaluate clinical efficacy and safety of adalimumab for moderate to severe psoriasis and investigate continuous versus interrupted therapy.METHODS:
We conducted a 52-week, multicenter study of 1212 patients randomized to receive adalimumab (40 mg) or placebo every other week for the first 15 weeks. At least 75% improvement in the Psoriasis Area and Severity Index (PASI) score was the criterion for advancement through this multiphase study.RESULTS:
At week 16, 71% (578 of 814) of adalimumab- and 7% (26 of 398) of placebo-treated patients achieved greater than or equal to 75% improvement in the PASI score. During weeks 33 to 52, the percentage of patients rerandomized to placebo who lost adequate response (defined as <50% improvement in the PASI response relative to baseline and at least a 6-point increase in PASI score from week 33) was 28% compared with 5% of patients treated continuously with adalimumab.LIMITATIONS:
Lack of an active comparator and evaluation of maintenance of response beyond week 52 are limitations.CONCLUSION:
Adalimumab is efficacious and well-tolerated in the treatment of chronic plaque psoriasis. TRIAL REGISTRATION Clinical trials.gov. NCT00237887.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos